Understanding Afrezza: Rapid-Acting Insulin via the Pulmonary Route

Afrezza is a dry-powder formulation of recombinant human insulin delivered through oral inhalation. Unlike traditional subcutaneously injected insulins that require absorption from adipose or muscle tissue, Afrezza exploits the unique physiology of the lung—specifically the extensive alveolar-capillary network that provides a large surface area (approximately 70–100 square meters in adults) and a thin diffusion barrier (less than 1 micrometer) for rapid drug transport. This design allows insulin monomers to enter the systemic circulation within 12–15 minutes of inhalation, with peak serum concentrations achieved in roughly 30–60 minutes. The onset of action is faster than that of regular human insulin or even rapid-acting analogs like lispro, aspart, or glulisine when given subcutaneously.

The formulation consists of Technosphere insulin—a complex of human insulin adsorbed onto microparticles of fumaryl diketopiperazine (FDKP). When these particles are inhaled and deposited in the deep lung, they dissolve at neutral pH, releasing monomeric insulin that crosses the alveolar epithelium and capillary endothelium with minimal degradation. The pharmacokinetic profile is characterized by a rapid rise in insulin levels, a sharp peak, and a quick return to baseline within 2–3 hours. This makes Afrezza especially suited for controlling postprandial glucose excursions when taken immediately before a meal. However, because the drug must transit the respiratory epithelium intact, any disruption in lung architecture, airway caliber, or alveolar membrane integrity directly alters its bioavailability and clearance dynamics.

The Pharmacokinetic Rationale for Pulmonary Insulin Delivery

The lung's ability to absorb large molecules like insulin is well documented. The alveolar epithelium is composed of type I and type II pneumocytes, with tight junctions that are relatively permeable compared to the gastrointestinal tract. Insulin, with a molecular weight of approximately 5.8 kDa, passes through these junctions and via transcytosis. The rapid absorption is also facilitated by the extensive capillary network underlying the alveoli, which provides immediate access to the systemic circulation without first-pass hepatic metabolism. This results in a time-action profile that mimics the endogenous insulin secretion pattern of a healthy pancreas in response to a meal—a rapid surge followed by a swift decline. For patients with diabetes, this profile can reduce late postprandial hypoglycemia compared to longer-acting injectable mealtime insulins.

Advantages and Limitations in Clinical Practice

Afrezza offers several meaningful advantages over injectable mealtime insulins. Needle-free administration reduces injection anxiety and needle-stick injuries, which is particularly beneficial for patients with needle phobia, children, or those requiring frequent daily injections. The faster onset (12–15 minutes versus 15–30 minutes for rapid-acting analogs) allows dosing at the start of the meal rather than 15–20 minutes beforehand, which can improve adherence. The quicker offset (3 hours versus 4–5 hours) reduces the risk of late hypoglycemic events between meals. However, these benefits come with important limitations. Absorption can be variable in patients with any degree of lung disease, there is a potential for gradual decline in lung function with long-term use, and there is a measurable incidence of acute bronchospasm and cough, especially in individuals with underlying airway hyperreactivity. These factors mandate careful baseline assessment and ongoing pulmonary surveillance.

The Foundational Role of Lung Function Tests in Afrezza Therapy

Lung function tests—primarily spirometry—provide objective, reproducible measurements of pulmonary mechanics and gas exchange capacity. The most clinically relevant parameters for Afrezza management are Forced Expiratory Volume in one second (FEV1) and Forced Vital Capacity (FVC). The FEV1/FVC ratio differentiates obstructive from restrictive ventilatory patterns. In specialized settings, diffusing capacity for carbon monoxide (DLCO) may also be assessed to evaluate the integrity of the alveolar-capillary membrane, which is the primary site of insulin absorption.

Regulatory frameworks, including the FDA-approved prescribing information for Afrezza, mandate baseline spirometry before initiating therapy and periodic monitoring thereafter. The specific requirements include measuring FEV1 at baseline, within 30 minutes after the first dose to detect acute bronchospasm, and then every 6–12 months during treatment. If a decline of 20% or more in FEV1 from baseline is observed, therapy must be reevaluated and likely discontinued. These requirements are not regulatory overreach—they are evidence-based safeguards grounded in the physiological reality that the lung is both the delivery route and a potential site of adverse effects.

How Spirometry Is Performed and Interpreted in the Clinical Setting

Spirometry is a straightforward but technique-dependent test. The patient takes a maximal inspiration and then exhales forcefully and completely into a calibrated device. The resulting flow-volume curve yields FEV1, FVC, peak expiratory flow (PEF), and other parameters. Predicted normal values are adjusted for age, sex, height, and ethnicity. In clinical practice for Afrezza candidacy, a pre-treatment FEV1 of at least 80% of predicted is generally considered the minimum acceptable threshold, though this can be adjusted based on individual risk factors and the presence of comorbid conditions. Values below 70% of predicted prompt careful risk-benefit analysis, and values below 50% of predicted are considered absolute contraindications due to safety concerns and predictable reductions in efficacy. It is important that spirometry is performed by trained personnel using equipment that meets American Thoracic Society/European Respiratory Society standards to ensure reproducibility and reliability.

Beyond FEV1: Additional Pulmonary Parameters of Interest

While FEV1 is the primary metric, other parameters add valuable context. The FEV1/FVC ratio helps classify whether any reduction in FEV1 is due to obstruction (ratio below 0.70) or restriction (ratio normal or elevated). A low DLCO indicates impaired alveolar-capillary gas transfer, which correlates with reduced insulin absorption capacity. Peak expiratory flow variability over time can signal evolving airway hyperreactivity. For patients with borderline spirometry, a bronchodilator challenge test (spirometry before and after inhaled albuterol) can identify reversible airway obstruction that might be managed with pre-treatment. Additionally, pulse oximetry at rest and with exertion can screen for clinically silent hypoxemia that might affect treatment tolerance.

How Lung Health Directly Impacts Afrezza Absorption and Efficacy

The efficacy of Afrezza is contingent on consistent and adequate delivery of insulin to the alveolar surface. Conditions that impair airflow—such as asthma, chronic obstructive pulmonary disease (COPD), acute bronchitis, or even viral upper respiratory infections—can reduce the fraction of the inhaled dose that reaches the deep lung. Even subclinical airway obstruction, defined as FEV1 between 70% and 80% of predicted without symptoms, can produce significant variability in insulin absorption, leading to unpredictable postprandial glucose control and increased risk of both hypoglycemia and hyperglycemia.

Structural alterations in the lung parenchyma further complicate absorption. In emphysema, the destruction of alveolar walls reduces the surface area available for drug transfer and increases the distance insulin must diffuse to reach the capillaries. In pulmonary fibrosis, the thickened alveolar-capillary barrier slows absorption and reduces peak insulin levels. In a seminal open-label pharmacokinetic study, patients with mild-to-moderate COPD (GOLD stage 1–2) demonstrated approximately 30% lower insulin exposure (measured by area under the curve, AUC) compared to healthy age-matched controls, with a corresponding reduction in glucose-lowering effect. This finding directly establishes that lung function tests are not optional screening tools but integral components of personalized Afrezza dosing algorithms. Without them, clinicians are effectively dosing blind.

The Mechanisms of Bronchospasm and Cough

Inhaled insulin can provoke acute bronchospasm, particularly in individuals with underlying airway hyperreactivity. The mechanism is thought to involve direct irritation of airway sensory nerves by the dry powder formulation, triggering reflex bronchoconstriction. In clinical trials, an average acute decline in FEV1 of approximately 40 mL was observed within 30 minutes of dosing, though this was generally reversible either spontaneously or with bronchodilator therapy. Patients with pre-existing asthma showed larger drops (mean 80–100 mL) and were at greater risk for persistent cough, wheezing, or chest tightness. Cough is the most common adverse event, occurring in up to 30% of patients in some trials, but it is typically mild and diminishes with continued use. Baseline spirometry helps identify patients who may need prophylactic bronchodilator use before Afrezza dosing or who should be excluded from therapy altogether. A post-dose spirometry reading that shows a decline in FEV1 of more than 15% from baseline is a clear red flag requiring immediate clinical action.

Clinical Evidence: The Relationship Between Lung Function and Afrezza Outcomes

Multiple prospective trials have systematically examined how baseline lung function modifies Afrezza efficacy and safety. A pooled analysis of phase 3 clinical trials that included over 2,000 patients with type 1 and type 2 diabetes demonstrated a clear gradient of benefit based on FEV1. Patients with baseline FEV1 at or above 90% of predicted achieved mean reductions in HbA1c of 0.8% to 1.2% and significantly better postprandial glucose control compared to those with FEV1 in the 60% to 80% range, who showed mean HbA1c reductions of only 0.4% to 0.6%. The incidence of treatment-related cough was also stratified by lung function: 22% in the high-FEV1 group versus 35% in the low-FEV1 group, and cough-related discontinuation was three times higher in the lower-function group.

Long-term safety data from the Affinity 1 open-label extension trial, which followed patients for two years, provided critical information about pulmonary safety. The trial found a small but statistically significant decline in FEV1 with continued Afrezza use—an average of 50–60 mL per year in the first year, compared to the expected age-related decline of 20–25 mL per year in the general diabetic population. However, this decline appeared to plateau after the first 12 months in most patients, suggesting an initial adaptive response rather than progressive pulmonary toxicity. Importantly, patients with baseline FEV1 below 70% of predicted experienced a rate of decline nearly twice that of patients with normal baseline function, and they were more likely to develop persistent cough or bronchospasm. This dose-response relationship between baseline lung health and adverse outcomes reinforces the need for strict patient selection and vigilant monitoring.

For additional clinical context, the FDA-approved prescribing information provides a complete summary of safety outcomes, contraindications, and required monitoring schedules. A comprehensive review published in Diabetes Care discusses the pharmacodynamics of inhaled insulin across a spectrum of pulmonary disease states and offers practical recommendations for clinicians (DOI: 10.2337/dc12-0515).

Patient Selection and Screening for Afrezza Therapy

Thoughtful patient selection is the first line of defense against adverse outcomes and treatment failure. The ideal candidate for Afrezza is a non-smoker (or a former smoker who quit more than six months prior) with normal or only mildly reduced lung function, no history of asthma or COPD, and no recent or recurrent respiratory infections. A complete medical history must include targeted questions about dyspnea on exertion, chronic cough (especially at night or with exercise), wheezing, chest tightness, and occupational or environmental exposures to pulmonary irritants. A history of recurrent pneumonia, tuberculosis, or lung surgery also warrants caution.

Absolute contraindications for Afrezza therapy include:

  • Chronic obstructive pulmonary disease (COPD) with FEV1 below 50% of predicted
  • Asthma of any severity, due to the risk of severe bronchospasm
  • Active lung cancer or history of pneumonectomy
  • Severe pulmonary hypertension (World Health Organization class III or IV)
  • Unresolved respiratory infection or acute bronchospasm at the time of initiation

Relative contraindications, which require careful risk-benefit assessment and often pulmonology consultation, include:

  • Mild, intermittent asthma with normal baseline spirometry
  • COPD with FEV1 between 50% and 80% of predicted
  • History of recurrent bronchitis or pneumonia
  • Current smoking or smoking cessation within the past six months
  • Any chronic lung disease, including bronchiectasis or pulmonary fibrosis

In these relative situations, a bronchodilator challenge test and a supervised first-dose inhalation with peak flow monitoring before and after dosing may be warranted. Documented informed consent that specifically addresses pulmonary risks should be obtained.

Establishing Baseline Lung Function Thresholds

While the FDA label does not prescribe rigid numerical cutoffs for all situations, clinical practice guidelines from endocrine and pulmonary societies suggest the following framework:

  • FEV1 ≥ 80% predicted: Acceptable for initiation without additional precautions beyond standard monitoring.
  • FEV1 60%–79% predicted: Proceed with caution. Consider slower dose titration, more frequent monitoring (every 3–4 months), and have bronchodilator therapy available. Discuss with pulmonology if feasible.
  • FEV1 50%–59% predicted: Initiation is generally not recommended. Consider only under expert guidance with intensive monitoring and clear patient understanding of risks.
  • FEV1 below 50% predicted: Contraindicated. Alternative injectable insulin regimens should be used.

These thresholds should be considered starting points. Individual patient circumstances, including rate of prior lung function decline, comorbidities, and patient preference, should be integrated into the final decision. Always confirm that the patient can perform spirometry with acceptable technique and reproducibility before using these values for clinical decisions.

Ongoing Monitoring During Treatment: Frequency and Clinical Interpretation

Once Afrezza therapy begins, lung function monitoring becomes a dynamic, ongoing responsibility. The recommended schedule, informed by regulatory requirements and clinical best practices, includes the following elements:

  • Baseline: Complete spirometry (pre- and post-bronchodilator if there is any suspicion of airway reactivity), repeated within 30 minutes after the first dose specifically to detect acute bronchospasm.
  • Monthly for the first three months: Office-based spirometry or at minimum, peak flow measurements. Many practices also instruct patients on home peak flow self-monitoring between visits.
  • Every 6–12 months thereafter: Full spirometry with FEV1, FVC, and FEV1/FVC ratio. If DLCO measurement is available, it should be included at the 12-month mark.
  • As needed: Immediate spirometry if new respiratory symptoms develop (cough, wheeze, dyspnea, chest tightness), if glycemic control deteriorates without clear explanation, or if there is an intercurrent respiratory infection.

Interpretation of trends requires a systematic approach. A decline in FEV1 of 10% or more from baseline within the first year should trigger a repeat measurement within two weeks. If the decline is confirmed on two consecutive readings separated by at least one week, the patient should be evaluated for reversible causes such as infection, allergen exposure, medication non-adherence, or occupational irritants. If no reversible cause is found, a discussion about transitioning to alternative diabetes therapies should begin. A decline of 20% or more from baseline at any point demands immediate discontinuation of Afrezza and prompt referral to a pulmonologist if not already involved.

Home Peak Flow Monitoring: Empowering Patients

Home peak flow monitoring is a practical, low-cost strategy to improve safety and patient engagement. Patients can use a simple peak flow meter each morning before their first dose, recording the best of three efforts. They should be taught to recognize a persistent decline below 80% of their personal best (established over the first two weeks of therapy) as a signal to contact their healthcare provider. This practice enables early detection of gradual deterioration that might otherwise be missed between scheduled clinic visits. Studies have shown that patients who engage in home monitoring have earlier detection of pulmonary adverse events and fewer unplanned hospital visits. The peak flow meter should be provided at the time of Afrezza initiation along with clear written instructions on when and how to report changes.

Managing Patients with Pre-existing Lung Conditions

Given the contraindications, many patients with asthma or COPD are not candidates for Afrezza. However, there is a narrow population with well-controlled, mild pulmonary disease who may still benefit after thorough evaluation. For patients with intermittent asthma (defined as symptoms less than twice per week and normal baseline FEV1), a bronchoprovocation test (e.g., methacholine or mannitol challenge) can quantify airway hyperresponsiveness before the first insulin dose. A negative challenge test provides reassurance that the risk of acute bronchospasm is low. If Afrezza is initiated in such a patient, a short-acting bronchodilator (albuterol) should be prescribed and immediately available at all times.

For patients with COPD, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging system is the best predictor of outcomes. GOLD stage 1 (mild) patients with FEV1 at or above 80% of predicted and no history of frequent exacerbations may tolerate Afrezza, though efficacy will likely be reduced compared to patients with normal lungs. GOLD stage 2 (moderate) or higher patients should avoid Afrezza due to the unacceptable risk of acute bronchospasm and the significant reduction in insulin absorption. A 2019 observational study of 140 patients with GOLD stage 1 COPD who used Afrezza found that only 40% achieved target postprandial glucose levels below 180 mg/dL, compared to 85% in an age- and HbA1c-matched control group without COPD. The same study reported a 22% rate of moderate-to-severe coughing episodes in the COPD group versus 8% in controls.

The American Diabetes Association and the European Association for the Study of Diabetes jointly recommend that any patient with a diagnosis of chronic lung disease should have a formal pulmonology evaluation before Afrezza initiation (DOI: 10.2337/dci20-0044). This consultation should include spirometry, a chest X-ray if not performed in the prior 12 months, and a discussion of the specific risks and expected benefits for that individual patient.

Transitioning to Alternative Therapies When Lung Function Declines

When Afrezza must be discontinued due to confirmed lung function decline, a structured transition plan is needed to maintain glycemic stability and avoid gaps in insulin coverage. The most straightforward switch is to a rapid-acting insulin analog such as lispro, aspart, or glulisine administered by subcutaneous injection. These insulins have a slightly slower onset (15–20 minutes versus 12–15 minutes) and a longer duration (3–5 hours versus 2–3 hours), so dose adjustments and meal timing require recalibration. A common approach is to begin with the same number of units per meal as the Afrezza dose (because the insulin content is equivalent), but to administer the injection 10–15 minutes before the meal rather than at the start of the meal. Close glucose monitoring for the first week of transition is essential to fine-tune dosing and timing.

For patients who strongly prefer non-injectable options, alternatives are limited. Exubera, the first FDA-approved inhaled insulin, was withdrawn for commercial reasons in 2007, and no other inhaled insulin formulation is currently approved for clinical use. Therefore, clinicians must work closely with patients to transition to injectable regimens, potentially using insulin pens with fine-gauge needles, needle-free injection devices, or insulin pumps to reduce the psychological burden of injections. The transition should be framed positively as a proactive safety measure rather than a treatment failure.

Another option for patients with type 2 diabetes is to adjust or add non-insulin agents that target postprandial glucose, including GLP-1 receptor agonists (e.g., liraglutide, semaglutide), DPP-4 inhibitors, or amylin analogs (pramlintide). While these agents are not direct replacements for mealtime insulin, they can reduce the total insulin dose required, which may allow continued use of Afrezza at a lower, potentially safer level if the decline in lung function is mild and stable. This approach requires careful coordination between the diabetes care team and a pulmonologist to establish safe parameters for continued use.

Integrating Lung Health into Routine Diabetes Care: Practical Recommendations

The connection between lung function tests and Afrezza treatment outcomes is not an academic detail—it is a core component of safe prescribing and effective diabetes management. For health systems and clinics that prescribe Afrezza, establishing a standardized workflow can ensure consistent adherence to monitoring protocols. This workflow should include: (1) a pre-screening checklist that includes respiratory history and smoking status, (2) a referral pathway to spirometry testing before the first prescription is written, (3) a template for documenting baseline FEV1 and the post-first-dose reading, (4) programmed reminders for follow-up spirometry at 6 and 12 months, and (5) a clear escalation protocol for declining lung function that includes when to discontinue the drug and how to transition to alternatives.

Patient education materials should cover the rationale for lung function testing in plain language, the technique for home peak flow monitoring, and specific symptoms that warrant immediate medical contact. Many patients do not intuitively link their diabetes therapy with pulmonary health, so explicit communication about why lung tests are needed and what the results mean is critical for adherence to the monitoring schedule.

The FDA's Afrezza prescribing information remains the definitive source for contraindications, dosing adjustments, and monitoring requirements. A thorough reading is recommended for any clinician who prescribes or manages patients on this therapy. Additionally, a clinical practice guideline from the Endocrine Society specifically addresses the role of inhaled insulin in diabetes management and provides consensus recommendations on patient selection and monitoring (DOI: 10.1210/jc.2017-02276).

In summary, lung function is not a static baseline but an ongoing vital sign that directly influences the safety and effectiveness of Afrezza therapy. Each spirometry reading provides actionable data that informs dosing, risk stratification, and the timing of transitions to alternative treatments. By respecting pulmonary physiology and embedding rigorous monitoring protocols into routine diabetes care, healthcare teams can offer the benefits of inhaled insulin to carefully selected patients while minimizing the risks to respiratory health.